GlassScriptPhysician profile
John Michael Rahe
NPI 1588740708
$2,094.34
in general payments reported to CMS, 2019-2025
20 companies · $65.08 in 2025
The $65.08 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $319 · 2021: $359 · 2022: $388 · 2023: $480 · 2024: $269 · 2025: $65.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $326.58 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $258.70 | 2019-2024 | Bexsero, Pediarix |
| Corium, LLC | $242.41 | 2021-2024 | Azstarys |
| Kaleo, INC. | $240.57 | 2019-2023 | Auvi-Q |
| Ironshore Pharmaceuticals INC. | $183.12 | 2019-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $170.59 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.97 | 2019-2022 | |
| Tris Pharma INC | $108.43 | 2019-2023 | Dyanavel Xr |
| Pfizer INC. | $87.18 | 2019-2022 | |
| Sanofi Pasteur INC. | $60.06 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $44.98 | 2023-2024 | Ycanth |
| Biomarin Pharmaceutical INC. | $42.49 | 2024 | Voxzogo 1.2mg |
| Neos Therapeutics, LP | $40.00 | 2019-2024 | Cotempla Xr-Odt |
| Astrazeneca Pharmaceuticals LP | $31.61 | 2023 | Flumist Quadrivalent |
| Noven Therapeutics, LLC | $30.12 | 2023 | Xelstrym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $28.97 | 2020 | |
| Tempus Ai, INC | $24.28 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $18.84 | 2025 | Zoryve |
| Genentech USA, INC. | $14.32 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rahe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.